Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B-cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is un...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yang, Yibin, Shaffer, Arthur L., Emre, N.C. Tolga, Ceribelli, Michele, Zhang, Meili, Wright, George, Xiao, Wenming, Powell, John, Platig, John, Kohlhammer, Holger, Young, Ryan M., Zhao, Hong, Yang, Yandan, Xu, Weihong, Buggy, Joseph J., Balasubramanian, Sriram, Mathews, Lesley A., Shinn, Paul, Guha, Rajarshi, Ferrer, Marc, Thomas, Craig, Waldmann, Thomas A., Staudt, Louis M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4059833/
https://ncbi.nlm.nih.gov/pubmed/22698399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.05.024
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller